Biotech Company Regenerates Tendons, Hair and Skin.

Share it

In a pre-clinical study a Canadian regenerative medicine biotech company RepliCel Life Sciences successfully regenerated skin and stimulated hair growth in pigs with burns and abrasions therapy: resulting in scarless healing, growth of hair follicles, complete wound coverage, and the progressive regeneration of all skin layers and tendons.

The company focuses on the development of a cell therapy using patient’s own cells. It is developing treatments targeted at healing chronic tendonitis caused by acute and chronic tendon overuse (where injuries that have failed to heal properly), hair restoration, and the treatment of UV damaged, burned and aged skin.

RepliCel is a development-stage company partnering with larger companies in Japan and may be including the United StatesEurope, and the Middle East to commercialize on (hopefully) a global scale. One such potential Licensing Agreement is already in place with one of the oldest cosmetics companies in the world, Shiseido Company. A Japanese multinational personal care company: skin care, hair care, cosmetics, and fragrance producer with vested interest in RepliCel therapies with the help of CJ Partners, the country’s leading business development experts in regenerative medicine

Their long term goal is to develop aesthetic and orthopedic-focused products involving a local injection of a patient’s own stem cells (autologous cell therapy) into areas where the resident cells are no longer capable of meeting demand.

Overview of new therapies:

RCT-01: In a Phase 1/2 single-center trial for tendonitis the use of the company’s type 1 collagen-expressing, follicle-derived fibroblast cell therapy showed promising results for a treatment for chronically injured tendons.

RCS-01: For skin rejuvenation patients suffering aging and UV damaged skin Repli-cell has been successful in a Phase 1 single-center trial  using the type 1 collagen-expressing, follicle-derived fibroblast cell therapy for a potential skin rejuvenation.

RCH-01: Treatment of patients with male/female pattern hair loss has been successfully tested in a Phase 1 single-center trial using the company’s dermal sheath cup cell therapy for hair regeneration. Clinical testing at Tokyo Medical University Hospital and Toho University Ohasi Medical Center is underway. The study is funded by Shiseido Company, who RepliCel has a licensing and financing arrangement with in Asia.

RCI-02: Dermal injector device (first of numerous devices) the company believes its dermal injection-related patents will lead. It’s designed for the injection of hyaluronic acid-based dermal fillers however it will be capable of being used for other products with similar injection profiles. 

This is very good news for the study of Gerontology, postponing or even reversing the Silver Tsunami is a major  goal in a community of scientists working to solve or even cure and reverse aging, the “root of most disease.”  Could we be making the elderly look and feel like their younger selves again sooner than we thought and will this eventually be affordable for everyone? Hopefully! We will see!

Resources: 

[1] https://medicalresearch.com/stem-cells/replicell-developing-autologous-ell-therapies/34087/

[2] https://www.forbes.com/sites/robinseatonjefferson/2017/09/29/company-uses-patients-own-cells-to-put-an-end-to-baldness-aging-skin-and-tendon-degeneration/

[3] http://markets.businessinsider.com/news/stocks/RepliCel-s-Partnership-Initiatives-Mature-into-Licensing-Negotiations-1002365340

Post Author: Carla Parsons

Leave a Reply

Your email address will not be published. Required fields are marked *